CAD-ILD GERD Assessment

GERD is significantly more prevalent in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD) compared to the general population, with prevalence exceeding 90% in systemic sclerosis patients. The relationship is bidirectional: CTD causes esophageal dysmotility and lower esophageal sphincter dysfunction, while GERD contributes to ILD progression through microaspiration of gastric contents into the lungs. Studies demonstrate that untreated GERD in CTD-ILD patients is associated with accelerated decline in forced vital capacity (FVC) and increased fibrotic changes on high-resolution CT imaging. The CAD-ILD-GERD assessment tool evaluates symptom frequency and severity across three domains (heartburn, regurgitation, dysphagia) plus additional risk factors (chronic cough, aspiration events, sleep disruption, PPI response) to generate a comprehensive score (0-32 points) that stratifies patients into management categories. This systematic approach enables clinicians to identify high-risk patients who may benefit from aggressive anti-reflux therapy, potentially slowing ILD progression and improving respiratory outcomes. Early identification is particularly crucial because GERD in CTD-ILD is often asymptomatic or minimally symptomatic, yet still contributes to lung damage through silent aspiration.

The CAD-ILD-GERD score combines symptom assessments with risk factors to generate a total score out of 32 points. Symptom scoring multiplies frequency (0-4: never, monthly, weekly, daily, multiple times daily) by severity (0-4: none, mild, moderate, severe, very severe) for three domains: heartburn (maximum 16 points), regurgitation (maximum 16 points), and dysphagia (maximum 16 points). Additional risk factors add points: chronic cough (+2), history of aspiration events (+3), sleep disruption (+2), and benefit from PPI therapy (+1). The total score stratifies patients into four severity categories: Minimal (0-5 points) indicates low ILD impact with conservative management recommended including lifestyle modifications; Mild-Moderate (6-12 points) suggests moderate ILD impact warranting PPI trial at standard doses (omeprazole 20-40mg daily); Moderate-Severe (13-20 points) indicates high ILD impact requiring aggressive medical management with high-dose PPI (double standard dose), possible H2 blocker addition, prokinetic agents, and upper endoscopy with pH monitoring; Severe (≥21 points) represents very high ILD impact with maximum medical therapy and surgical consultation for potential anti-reflux surgery (Nissen fundoplication). For example, a systemic sclerosis patient with daily severe heartburn (3×3=9), daily moderate regurgitation (3×2=6), weekly mild dysphagia (2×1=2), chronic cough (+2), and aspiration history (+3) would score 22 points (severe category), triggering surgical evaluation.

Multiple interconnected mechanisms explain how GERD contributes to ILD progression in CTD patients. Microaspiration represents the primary pathway: gastric acid and pepsin enter the airways during reflux events, particularly during supine positioning and sleep, causing direct chemical injury to bronchial epithelium and alveolar tissue. Studies using lipid-laden macrophage analysis and technetium-99m scintigraphy demonstrate aspiration in 30-60% of CTD-ILD patients with GERD. Vagally-mediated bronchoconstriction occurs when acid in the distal esophagus triggers reflexive airway narrowing through vagal pathways, exacerbating dyspnea without requiring actual aspiration. Esophageal dysmotility, particularly common in systemic sclerosis, results from smooth muscle atrophy and fibrosis, reducing esophageal clearance efficiency and prolonging acid exposure time. Lower esophageal sphincter (LES) dysfunction with pressures falling below 10 mmHg (normal 15-30 mmHg) permits increased reflux episodes. Delayed gastric emptying from autonomic dysfunction increases gastric volume and reflux frequency. Chronic inflammation from repeated micro-aspirations promotes fibroblast activation, collagen deposition, and progressive fibrosis through TGF-β and other pro-fibrotic cytokines. Additionally, immunosuppressive medications used for CTD treatment may impair local immune responses to aspirated material, amplifying lung injury. The combination of these mechanisms creates a self-perpetuating cycle where GERD accelerates ILD progression, which in turn may worsen GERD through increased intrathoracic pressure and diaphragmatic dysfunction.

GERD management requires disease-specific considerations based on the underlying connective tissue disorder. Systemic sclerosis (scleroderma) presents the most severe challenges with GERD prevalence exceeding 90% and marked esophageal dysmotility from smooth muscle fibrosis. These patients typically require aggressive empiric therapy regardless of symptoms, including twice-daily high-dose PPI (esomeprazole 40mg BID), prokinetic agents (metoclopramide 10mg before meals), and nocturnal H2 blocker (ranitidine 300mg at bedtime) to prevent nocturnal acid breakthrough. Esophageal manometry often reveals aperistalsis in the distal two-thirds and LES pressures below 10 mmHg, making surgical fundoplication risky due to impaired esophageal clearance. Rheumatoid arthritis patients develop GERD partly from medications (NSAIDs, methotrexate, corticosteroids) that directly damage gastric mucosa. Management emphasizes gastroprotection with PPI therapy concurrent with NSAID use and consideration of selective COX-2 inhibitors. Dermatomyositis and polymyositis involve inflammatory myopathy affecting pharyngeal and upper esophageal muscles, increasing aspiration risk independent of GERD severity. These patients benefit from videofluoroscopic swallow studies, dietary modifications (thickened liquids, pureed foods), and sometimes feeding tube placement for severe dysphagia. Sjögren's syndrome features reduced saliva production, which impairs esophageal acid clearance and increases GERD severity. Treatment includes frequent water sips, sugar-free gum, and pilocarpine (5mg TID) to stimulate saliva production alongside standard PPI therapy. Mixed CTD requires individualized assessment combining elements from multiple disease-specific approaches.

Multiple diagnostic modalities assess GERD and its pulmonary impact in CTD-ILD patients, with selection based on clinical presentation and treatment planning. 24-hour esophageal pH monitoring remains the gold standard for GERD diagnosis, measuring acid exposure time (abnormal if pH <4 for >4.2% of total time), number of reflux episodes (abnormal if >50 episodes/24 hours), and symptom correlation through symptom index. Multichannel intraluminal impedance-pH monitoring (MII-pH) detects both acid and non-acid reflux events, particularly important in CTD patients on PPI therapy where persistent symptoms may reflect non-acid reflux. Studies show 30-40% of CTD-ILD patients have persistent reflux on PPI therapy detected only by impedance testing. Esophagogastroduodenoscopy (EGD) visualizes erosive esophagitis (Los Angeles classification grades A-D), Barrett's esophagus (present in 5-10% of long-standing GERD), and hiatal hernias (found in 40-60% of systemic sclerosis patients). Esophageal manometry assesses motility disorders, revealing aperistalsis or ineffective esophageal motility in 70-80% of systemic sclerosis patients and helping predict fundoplication outcomes. Bronchoalveolar lavage (BAL) with lipid-laden macrophage index >100 suggests chronic aspiration, while pepsin assays in BAL fluid directly demonstrate gastric content aspiration. High-resolution CT chest may show tree-in-bud opacities, centrilobular nodules, or basilar-predominant fibrosis suggesting aspiration-related lung injury. Nuclear gastric emptying studies identify delayed emptying contributing to GERD severity, guiding prokinetic therapy decisions. For example, a systemic sclerosis patient with UIP pattern ILD showing esophageal aperistalsis on manometry, 8.2% acid exposure time on pH study, and lipid-laden macrophages in BAL demonstrates clear GERD-ILD connection requiring aggressive treatment.

Anti-reflux surgery, typically laparoscopic Nissen fundoplication, should be considered in CTD-ILD patients with documented severe GERD who fail maximum medical therapy (high-dose BID PPI plus H2 blocker) or demonstrate progressive ILD despite medical management. Ideal surgical candidates have objective GERD confirmation (abnormal pH monitoring showing >6% acid exposure time), large hiatal hernia, preserved esophageal peristalsis on manometry (>70% wet swallows with effective contractions), and willingness to accept permanent dietary modifications. Systemic sclerosis patients require careful evaluation because esophageal aperistalsis increases post-fundoplication dysphagia risk; however, selected patients with early disease and preserved proximal esophageal function may benefit from partial fundoplication (Toupet 270-degree wrap) rather than complete 360-degree Nissen, reducing dysphagia while controlling reflux. Pre-operative workup must include high-resolution manometry, timed barium esophagram to assess emptying, and sometimes gastric emptying study to exclude gastroparesis requiring concurrent pyloroplasty. Surgical outcomes data show 70-85% GERD symptom improvement in carefully selected CTD patients, with stabilization of FVC decline in 60-70% of cases post-operatively. A landmark study of systemic sclerosis-ILD patients undergoing fundoplication demonstrated average FVC stabilization at 1-year follow-up versus continued 4.2% annual decline in matched controls with medical therapy alone. However, complication rates are higher in CTD populations: 15-25% develop persistent dysphagia requiring endoscopic dilation, 10-15% require conversion to partial wrap, and 5-10% need fundoplication takedown. Post-operative management includes liquid diet for 2 weeks, pureed diet for 4 weeks, continued PPI therapy for 3 months, and lifelong dietary modifications (small frequent meals, avoiding carbonated beverages, remaining upright 3 hours post-meal). Multidisciplinary discussion involving pulmonology, gastroenterology, rheumatology, and thoracic surgery is essential for optimal patient selection and outcome optimization.